What is SS-31?
SS-31 is elamipretide, a mitochondria-targeted tetrapeptide/cardiolipin binder now approved in the United States for a narrow Barth syndrome indication and still researched across mitochondrial disease models.
SS-31 dosage snapshot
- Route
- subQ / IV research
- Dose range
- 5-40 mg
- Frequency
- daily or repeated dosing
- Duration
- 4-48 weeks in studies
Based on reported research sources; not a dosing instruction.
Potential benefits
- Cellular energy
- Healthy aging
- Mitochondrial support
- Recovery capacity
- Metabolic resilience
Safety profile
Unknown risk- Common: Route-specific irritation or tolerability issues may be reported depending on the compound.
- Less common: Headache, fatigue, appetite changes, or GI discomfort can appear in community or study contexts.
- Caution: Risk depends on dose, route, study model, duration, compound quality, and whether human data exists.
Storage and handling
Store according to product-label instructions and batch handling notes. Lyophilized research peptides are commonly kept dry, protected from light, and handled with clean laboratory technique.